ONMDOneMedNet Corp同业对比
OneMedNet Corp 与SIC 8731 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ONMD本股 | $251M#8 | — | — | 184.5x#12 | 111.4%#2 | 72.3%#2 | -711.3%#12 | — | — | 4#1 | -80.0%#10 | — |
| IQV | $43.5B#1 | 32.1x#3 | 6.5x#8 | 2.7x#4 | 5.9%#5 | -0.9%#6 | 13.4%#4 | 20.4%#4 | 9.0%#3 | — | 24.9%#5 | 1.3%#2 |
| INCY | $24.1B#2 | 60.4x#5 | 4.3x#6 | 4.7x#8 | 21.2%#3 | 3846.9%#1 | 29.5%#1 | 22.8%#3 | 45.1%#1 | — | 16.5%#6 | — |
| MEDP | $18.8B#3 | 37.3x#4 | 32.1x#11 | 7.4x#10 | 20.0%#4 | 11.6%#4 | 21.1%#2 | 77.1%#2 | — | — | 13.1%#7 | — |
| CRL | $16.9B#4 | — | 5.9x#7 | 4.2x#7 | -0.9%#6 | -750.1%#14 | 0.6%#5 | -5.1%#5 | 0.6%#4 | — | 97.5%#3 | — |
| ABSI | $1.7B#5 | — | 7.1x#10 | 620.3x#13 | -38.2%#12 | -11.7%#9 | -4297.0%#13 | -46.8%#8 | -84.6%#5 | — | 146.8%#2 | — |
| OABI | $738M#6 | — | 3.0x#5 | 39.5x#11 | -29.3%#9 | -4.4%#7 | -369.5%#10 | -26.0%#6 | — | — | 243.1%#1 | — |
| NRC | $531M#7 | 0.5x#2 | 81.1x#12 | 3.9x#5 | -4.0%#7 | -53.2%#10 | 16.4%#3 | 177.1%#1 | 15.7%#2 | — | 85.5%#4 | 2.1%#1 |
| MXCT | $147M#9 | — | 0.9x#3 | 7.0x#9 | -5.7%#8 | -8.7%#8 | -247.6%#9 | -28.1%#7 | — | — | -11.5%#8 | — |
| BIAF | $26M#10 | — | 6.8x#9 | 4.2x#6 | -34.2%#10 | -64.9%#11 | -171.6%#7 | -395.6%#9 | -661.2%#8 | — | -90.9%#11 | — |
| BIAFW | $3M#11 | — | 0.7x#2 | 0.4x#2 | -34.2%#10 | -64.9%#11 | -171.6%#7 | -395.6%#9 | -661.2%#8 | — | -58.8%#9 | — |
| ISPC | $2M#12 | 0.0x#1 | 1.3x#4 | 1.1x#3 | -79.2%#13 | 16.1%#3 | -465.4%#11 | -604.0%#11 | -511.9%#7 | — | -97.0%#12 | — |
| FOXO | $150889#13 | — | 0.2x#1 | 0.0x#1 | 304.0%#1 | -0.2%#5 | -63.1%#6 | -1257.7%#12 | -268.4%#6 | — | -100.0%#13 | — |
| BUDZ | — | — | — | — | — | -168.7%#13 | — | — | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-04。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议